Duloxetine Side Effects
Not all side effects for duloxetine may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to duloxetine: oral capsule, oral capsule delayed release
In addition to its needed effects, some unwanted effects may be caused by duloxetine. In the event that any of these side effects do occur, they may require medical attention.
You should check with your doctor immediately if any of these side effects occur when taking duloxetine:Incidence not known
- Abdominal or stomach pain
- area rash
- blistering, peeling, or loosening of the skin
- blurred vision
- change in consciousness
- clay-colored stools
- cold sweats
- dark urine
- decreased urine output
- decreased vision
- difficulty swallowing
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- eye pain
- fast or irregular heartbeat
- general tiredness or weakness
- hives or welts
- hives, itching, puffiness, or swelling of the eyelids or around the eyes, face, lips, or tongue
- increased thirst
- joint or muscle pain
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- light-colored stools
- loss of consciousness
- red skin lesions, often with a purple center
- red, irritated eyes
- redness of the skin
- shortness of breath
- skin rash
- sores, ulcers, or white spots in the mouth or on the lips
- swelling of the face, ankles, or hands
- tightness in the chest
- unpleasant breath odor
- upper right stomach pain
- vomiting of blood
- yellow eyes and skin
If any of the following symptoms of overdose occur while taking duloxetine, get emergency help immediately:Symptoms of overdose
- loss of bladder control
- muscle spasm or jerking of all extremities
- overactive reflexes
- poor coordination
- sleepiness or unusual drowsiness
- sudden loss of consciousness
- talking or acting with excitement you cannot control
- trembling or shaking
- unusual tiredness or weakness
Some of the side effects that can occur with duloxetine may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:More common
- Body aches or pain
- difficulty having a bowel movement (stool)
- difficulty with breathing
- dry mouth
- ear congestion
- frequent urination
- lack or loss of strength
- loss of appetite
- loss of voice
- muscle aches
- sleepiness or unusual drowsiness
- sore throat
- stuffy or runny nose
- sweating increased
- trouble sleeping
- unable to sleep
- weight loss
- Abnormal orgasm
- acid or sour stomach
- burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
- change in taste
- change or problem with discharge of semen
- decreased interest in sexual intercourse
- difficulty with moving
- feeling of warmth or redness of the face, neck, arms, and occasionally, upper chest
- inability to have or keep an erection
- joint pain
- longer than usual time to ejaculation of semen
- loose stools
- loss in sexual ability, desire, drive, or performance
- loss of taste
- muscle aching or cramping
- muscle pains or stiffness
- shakiness in the legs, arms, hands, or feet
- stomach discomfort, upset, or pain
- sudden sweating
- swollen joints
- trembling or shaking of the hands or feet
For Healthcare Professionals
Applies to duloxetine: oral delayed release capsule
The most commonly reported side effects reported in placebo-controlled clinical trials included nausea, dry mouth, somnolence, constipation, decreased appetite, hyperhidrosis, agitation, fatigue, insomnia, dizziness
The most commonly reported side effects reported in placebo-controlled clinical trials as a reason for treatment discontinuation and considered to be drug-related included nausea, dizziness, somnolence, headache, and fatigue.
Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between the use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding.
Very common (10% or more): Nausea, dry mouth, constipation, diarrhea
Common (1% to 10%): Abdominal pain, vomiting, dyspepsia, flatulence, dysgeusia
Uncommon (0.1% to 1%): Dysphagia, eructation, gastritis, gastrointestinal hemorrhage, halitosis, stomatitis, gastroenteritis, hematochezia
Rare (less than 0.1%): Gastric ulcer
Postmarketing reports: Gastrointestinal bleeding
Very common (10% or more): Headache, somnolence, dizziness
Common (1% to 10%): Paraesthesia/hypoesthesia, vertigo
Uncommon (0.1% to 1%): Myoclonus, convulsions, psychomotor restlessness, extrapyramidal symptoms, dyskinesia, restless legs syndrome
Rare (less than 0.1%): Gait disturbance
Postmarketing reports: Seizures upon treatment discontinuation, intracerebral bleeding
Nearly all selective serotonin reuptake inhibitors, mixed serotonin/norepinephrine reuptake inhibitors, and tricyclic antidepressants cause sleep abnormalities to some extent. These antidepressants have marked dose-dependent effects on rapid eye movement (REM) sleep, causing reductions in the overall amount of REM sleep over the night and delays the first entry into REM sleep (increased REM sleep onset latency (ROL)), both in healthy subjects and depressed patients. The antidepressants that increase serotonin function appear to have the greatest effect on REM sleep. The reduction in REM sleep is greatest early in treatment, but gradually returns towards baseline during long-term therapy; however, ROL remains long. Following discontinuation of therapy the amount of REM sleep tends to rebound. Some of these drugs (i.e., bupropion, mirtazapine, nefazodone, trazodone, trimipramine) appear to have a modest or minimal effect on REM sleep.
Antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. An increased risk of suicidal thinking and behavior in children, adolescents, and young adults (aged 18 to 24 years) with major depressive disorder (MDD) and other psychiatric disorders has been reported with short-term use of antidepressant drugs.
Adult and pediatric patients receiving antidepressants for MDD, as well as for psychiatric and nonpsychiatric indications, have reported symptoms that may be precursors to emerging suicidality, including anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, and mania. Causality has not been established.
Aggression and anger have been reported particularly early in treatment or after treatment discontinuation.
Very common (10% or more): Insomnia
Common (1% to 10%): Agitation, anxiety, abnormal dreams, sleep disorder
Uncommon (0.1% to 1%): Disturbance in attention, poor quality sleep, apathy, bruxism, disorientation/confusional state, irritability, mood swings, suicide attempt, nervousness
Rare (less than 0.1%): Dysarthria, suicidal behavior and ideation, completed suicide, mania, hallucinations, aggression and anger, akathisia
Common (1% to 10%): Decreased appetite, weight increase/decrease
Uncommon (0.1% to 1%): Increased blood cholesterol, dehydration, hyperlipidemia, hyponatremia, syndrome of inappropriate secretion of antidiuretic hormone (SIADH), increased blood creatine phosphokinase
Rare (less than 0.1%): Dyslipidemia, increased blood potassium
Frequency not reported: Increased bicarbonate, and abnormal potassium levels.
Postmarketing reports: Hyperglycemia
Although infrequent, several cases of duloxetine induced hyponatremia have been reported. In one case report, duloxetine induced hyponatremia was confirmed after inadvertent rechallenge. It has been suggested that there is a dose-related effect in the development of hyponatremia with duloxetine. Numerous cases of hyponatremia have been reported following treatment with an SSRI. Risk factors include advanced age, female gender, concomitant use of diuretics, low body weight, and lower baseline serum sodium levels.
Hyponatremia tends to develop within the first few weeks of treatment (range 3 to 120 days) and typically resolves within 2 weeks (range 48 hours to 6 weeks) after therapy has been discontinued with some patients requiring treatment (e.g., water restriction, dietary sodium). The proposed mechanism for the development of hyponatremia involves the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) via release of antidiuretic hormone.
Potentially life-threatening serotonin syndrome has been reported with SSRIs and SNRIs, including duloxetine as monotherapy, but particularly with concomitant use of other serotonergic drugs and drugs that impair the metabolism of serotonin.
Falls were reported more commonly in patients 65 years of age or older.
Very common (10% or more): Fatigue
Common (1% to 10%): Lethargy, asthenia, chills/rigors, pyrexia
Uncommon (0.1% to 1%): Ear pain, tinnitus, falls, feeling abnormal, feeling hot and/or cold, malaise, thirst
Postmarketing reports: Serotonin syndrome
Orthostatic hypotension and syncope tend to occur within the first week of therapy; however, they may occur at any time during treatment, particularly after dose increases. The risk of blood pressure decreases may be greater when duloxetine is given concomitantly with drugs that may induce orthostatic hypotension, such as antihypertensives, with potent CYP450 1A2 inhibitors, or with duloxetine doses above 60 mg per day.
Common (1% to 10%): Palpitations, flushing, hot flush, increased blood pressure, hypertension
Uncommon (0.1% to 1%): Myocardial infarction, tachycardia, orthostatic hypotension, peripheral coldness, syncope, chest pain
Rare (less than 0.1%): Supraventricular arrhythmia (mainly atrial fibrillation), hypertensive crisis
Postmarketing reports: Ventricular arrhythmias
The reporting rate of Stevens-Johnson syndrome associated with duloxetine exceeds the general population background incidence rate (1 to 2 cases per million person years).
Common (1% to 10%): Hyperhidrosis, pruritus
Uncommon (0.1% to 1%): Cold sweat, contact dermatitis, erythema, increased tendency to bruise, night sweats, photosensitivity reaction, urticaria
Rare (less than 0.1%): Ecchymosis, Stevens-Johnson syndrome
Postmarketing reports: Petechiae, erythema multiforme
Uncommon (0.1% to 1%): Hypothyroidism
Postmarketing reports: Hyperprolactinemia
The Arizona sexual experience scale, used to identify sexual side effects, was used prospectively in 4 major depressive disorder placebo-controlled trials showed that male patients treated with duloxetine experienced significantly more sexual dysfunction than patients treated with placebo.
Common (1% to 10%): Decreased libido, abnormal orgasm/anorgasmia, erectile dysfunction, delayed ejaculation, ejaculation disorder, urinary frequency
Uncommon (0.1% to 1%): Menopausal symptoms, sexual dysfunction, testicular pain, gynecological hemorrhage, dysuria, micturition urgency, nocturia, polyuria, abnormal urine odor, urinary hesitation, pollakiuria
Rare (less than 0.1%): Menstrual disorder, galactorrhea, urinary retention, decreased urine flow
Concomitant use of aspirin, NSAIDs, warfarin, and other anticoagulants may increase the risk of bleeding events associated with duloxetine.
Postmarketing reports: Life-threatening hemorrhage, hematomas, blood dyscrasias
Cases of liver failure, including fatalities, have been reported. The majority of cases were reported in patients with past or current risk factors for liver injury, including alcohol abuse, hepatitis, or exposure to drugs with known adverse effects on the liver.
Uncommon (0.1% to 1%): Hepatitis, elevated liver enzymes (ALT, AST, GGT, alkaline phosphatase), increased blood bilirubin, acute liver injury
Rare (less than 0.1%): Hepatic failure, jaundice
Postmarketing reports: Pancreatitis
Rare (less than 0.1%): Angioneurotic edema
Postmarketing reports: Anaphylactic reaction, hypersensitivity
Common (1% to 10%): Influenza
Common (1% to 10%): Tremor, musculoskeletal pain (including myalgia, neck pain), muscle spasms, back pain
Uncommon (0.1% to 1%): Muscle tightness (including musculoskeletal stiffness), muscle twitching, dyskinesia, trismus
Postmarketing reports: Rhabdomyolysis
Pupillary dilation that occurs following the use of many antidepressant drugs may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy.
Common (1% to 10%): Blurred vision
Uncommon (0.1% to 1%): Diplopia, dry eye, visual impairment, mydriasis
Rare (less than 0.1%): Glaucoma
Postmarketing reports: Renal impairment
Common (1% to 10%): Yawning, nasopharyngitis, upper respiratory tract infection, cough, oropharyngeal pain, pharyngolaryngeal pain
Uncommon (0.1% to 1%): Laryngitis, throat tightness
Rare (less than 0.1%): Epistaxis
More about duloxetine
- Other brands: Cymbalta
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.